Physician profile
Jerry Sebag
NPI 1689601635
$44,948.90
in general payments reported to CMS, 2019-2025
14 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,919 · 2021: $6,889 · 2022: $20K · 2023: $28.55 · 2024: $1,732 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,697 · Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,696.80 |
| Food and Beverage | $236.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $19,675.00 | 2022 | |
| F. Hoffmann-La Roche Ag | $12,536.73 | 2019-2024 | |
| Alcon Research LLC | $11,410.00 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $365.00 | 2019 | |
| Dutch Ophthalmic, USA | $157.77 | 2019 | |
| Alcon Vision LLC | $154.55 | 2019-2025 | Unity |
| Ocular Therapeutix, INC. | $135.98 | 2021 | |
| Eyevance Pharmaceuticals LLC | $125.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $116.79 | 2021 | |
| Abbvie INC. | $63.45 | 2023-2024 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $39.20 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $24.24 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Sebag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.